Angiolutions Appoints International Endovascular Experts to Its Medical Board

April 29, 2026—Angiolutions announced the appointment of four internationally recognized vascular and endovascular specialists to its Medical Board, which will support the company as it advances development of the investigational A3-Shield system. The device is designed to treat abdominal aortic aneurysms (AAAs) by locally modulating aortic pulse waves, noted the company.

The inaugural members of the Medical Board are:

• Professor Mark A. Farber, MD, of the University of North Carolina at Chapel Hill in Chapel Hill, North Carolina
• Prof. Tilo Kölbel, MD, of University Medical Center Hamburg in Hamburg, Germany
• Prof. Hubert Schelzig, MD, of University Medical Center Düsseldorf in Düsseldorf, Germany
• Prof. Peter Schneider, MD, of the University of California, San Francisco in San Francisco, California

The company stated that the board members have extensive clinical, scientific, and translational expertise in vascular surgery, endovascular therapies, and aortic disease management. They will provide strategic clinical guidance across product development, clinical investigation, and future adoption pathways as Angiolutions extends its clinical program.

The company seeks to provide a treatment option for patients with small aneurysms who are not eligible for conventional repair, noted Angiolutions.

Angiolutions Founders and Co-CEOs, Isabel N. Schellinger, MD, and Uwe Raaz, MD, commented on the appointments in the company’s press release.

“We are proud to welcome this outstanding group of physicians to the Angiolutions Medical Board,” stated Dr. Schellinger. “Their collective experience in vascular and endovascular care will be invaluable as we continue to develop the A3-Shield system and generate clinical evidence for a new treatment approach in patients with small AAAs. By working closely with leading experts in the field, we aim to accelerate our mission to offer patients an earlier therapeutic option.”

Dr. Raaz added, “Bringing together leading experts from renowned centers in the United States and Europe is an important step for Angiolutions. Their insights will be of utmost importance in shaping clinical strategy as we work to redefine how AAAs can be treated at an earlier stage.”